Cardiocomm Solutions Completes Mobile Cardiac Telemetry Software Release for Raytel Cardiac Services
25 Noviembre 2013 - 1:02PM
Access Wire
Raytel Cardiac Services will be the first to
launch into the American MCT monitoring market using the CardioComm
Solutions Wireless Arrhythmia Services Software
Toronto, Canada. -
CardioComm Solutions Inc. ( TSX-V:EKG)
("CardioComm Solutions" or the "Company") confirms the release of a
custom GEMSTM Mobile Cardiac Telemetry software ("GEMS M-Air")
solution with web-based device interfacing for use by Raytel
Cardiac Services Inc. ("Raytel"). The software license agreement
("SLA") was originally announced in February 2012 by the Company,
when Raytel was operated as a subsidiary of Royal Philips
Electronics ("Philips"). The completion of GEMS M-Air is the latest
addition to CardioComm Solutions' remote diagnostic arrhythmia and
remote patient monitoring solutions portfolio offerings.
The SLA called for
the development of a highly customized wireless ECG monitoring
solution utilizing the TZ Medical ("TZM") manufactured Aera CT TM
device ("Aera CT") and Raytel's existing CardioCare(R) Diagnostic
Arrhythmia Service ("CardioCare"). The solution was scheduled for release in two phases with the first
being a custom GEMSTM Air release which was announced by Philips at the 2013 Heart
Rhythm Society meeting. In June
2013, Lincare Inc. (Clearwater Florida) acquired sole rights over
Raytel and on November 9, 2013, CardioComm Solutions released the
full feature M-Air solution to Raytel for
implementation.
Global interest for GSM enabled remote cardiac
monitoring solutions continues to
increase and the United States is leading the demand with estimated
market revenues to reach $867M by 2016 (IHS InMedica, 2013).
"This M-Air project was an aggressive undertaking
aimed at enabling Raytel to offer mobile cardiac telemetry ("MCT")
monitoring with the benefit of utilizing the independently, FDA
cleared GEMSTM ECG
viewing and reporting software technology. M-Air
will now provide Raytel complete
MCT monitoring control and real-time access to patient's ECGs
using the
Aera CT device within their CardioCare
service," stated Carlos Somoza.
CardioComm Solutions is now planning release of
new GEMS and MCT based software
solutions. "Beta testing of GEMSTM 4 is underway and
we expect to have a commercial MCT module ready for testing before
the end of the year. Despite the FDA funding cuts and delays in
review of our GUAVA II 510K application, we are on track to enter
2014 to take a very competitive position
within the well reimbursed American MCT monitoring market. Further,
CardioComm Solutions will now have expanded recognition as a mobile
cardiac telemetry solutions provider to the growing ECG monitoring markets
in Canada, South America and overseas, global markets estimated to be worth $18.4 billion," said
Etienne Grima, Chief Executive Officer of CardioComm
Solutions.
About CardioComm Solutions
CardioComm Solutions'
patented and proprietary technology is used in products for
recording, viewing, analyzing and storing electrocardiograms (ECGs)
for diagnosis and management of cardiac patients. Products are sold
worldwide through a combination of an external distribution network
and a North American-based sales team. The Company has earned the
ISO 13485 certification, is HPB approved, HIPAA compliant, and has
received FDA market clearance for its software devices. CardioComm
Solutions, Inc. is headquartered in Toronto, Canada, with offices
in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
egrima@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking
statements with respect to the financial condition, results of
operations and business of CardioComm Solutions and certain of the
plans and objectives of CardioComm Solutions with respect to these
items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on
circumstances that will occur in the future and there are many
factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking
statements.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
CardioComm Solutions (TSXV:EKG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
CardioComm Solutions (TSXV:EKG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024